Felton Anderson, MD
Cardiovascular Disease · Washington, DCNPI 1588655914
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,413 of the $22,803 with a category attached, or 80.7%. It is spread thinly across 50 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Among cardiovascular disease clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 837 payments — averaging $27.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- AstraZeneca$3K
- Bayer$2K
- Eli Lilly$1K
- Pfizer$1K
- Amgen$1K
- plus $10K from 44 others
Across 77 payments — averaging $31,809 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.9M
- Eli Lilly$491K
- Pfizer$75K
- Regeneron$2K
What the payments were for
- Travel & lodging$4,28219%
- Food & beverage$18,41381%
- Education$1080%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$807
- BREZTRI$441
- AIRSUPRA$272
- Micra$174
- FARXIGA$169
- BRILINTA$169
- CardioMEMS HF System$155
- Assurity Pacemaker$148
- AVEIR$139
- Confirm Rx$137
- BIOPROTECT BALLOON IMPLANT SYSTEM$136
- LEQVIO$125
How this compares
$22,803 in reported general payments places this provider in the 90th percentile of 105 cardiovascular disease providers in District of Columbia.
See all cardiovascular disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $175,000 |
| EliquisApixaban | 151 | $166,833 |
| EntrestoSacubitril/Valsartan | 60 | $74,695 |
| MounjaroTirzepatide | 32 | $60,769 |
| JanuviaSitagliptin Phosphate | 61 | $58,253 |
| JardianceEmpagliflozin | 47 | $50,028 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $43,526 |
| XareltoRivaroxaban | 45 | $35,065 |
| TrulicityDulaglutide | 25 | $32,815 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $26,920 |
| BrilintaTicagrelor | 41 | $24,938 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $18,152 |
| TradjentaLinagliptin | 18 | $17,351 |
| FarxigaDapagliflozin Propanediol | 12 | $17,202 |
| LinzessLinaclotide | 28 | $15,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $654 | $175,000116 claims |
| PfizerEliquis | $1,104 | $166,833151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,013 | $93,58457 claims |
| MerckJanuvia, Janumet | $870 | $85,17383 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $817 | $75,21076 claims |
| NovartisEntresto | $4,844 | $74,69560 claims |
| AstraZenecaBrilinta, Breztri Aerosphere, Farxiga | $2,594 | $60,29279 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $926 | $53,94074 claims |
| Johnson & JohnsonXarelto | $118 | $35,06545 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $56 | $18,13851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 105 cardiovascular disease providers in District of Columbia.
Other cardiovascular disease in Washington
- Hayder HashimWashington$824K
- Joshua YamamotoWashington$376K
- Mardi Gomberg-MaitlandWashington$320K
- Jaffar KhanWashington$318K
- Isaac Opoku-AsareWashington$146K
- Judith HsiaWashington$65K
- Ana BaracWashington$34K
- Jonathan PlehnWashington$32K
- Andrew ChoiWashington$32K
- Jose VargasWashington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.